HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Despite the limited effectiveness of HDAC inhibitors as a single agent therapy in ovarian cancer and other solid tumors, the HDAC inhibitors vorinostat and romidepsin have been remarkably effective in the treatment of CTCL [14-19].